As of November 2022, Oncomine DxTT can support the detection of five driver genes (EGFR mutation, ALK fusion gene, ROS1 fusion gene, BRAF V 600 E mutation, and RET fusion gene) in NSCLC and the determination of indications for treatment with 11 molecularly targeted drugs (6). Here, ALK is linked to non-small cell lung carcinoma.